Henry Meds tirzepatide: November 2026 price and position
As of November 20, 2026, no current compounded tirzepatide price is shown for Henry Meds: its page read on its own page on November 20, 2026 (changed since the last read). This record shows no figure rather than an outdated one presented as current.
Released · Last reviewed · how we verify
Why no current price is shown
Semaglutide $297 a month ($197 a month if 12 months are paid in full) on its legal programs price list dated December 3, 2025; no injectable tirzepatide price printed. The August 2026 capture stays in the open dataset with its date. For programs that do print a tirzepatide price, see the tirzepatide price table.
Limitations and what to check before you enroll
Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound; it is made for an individual patient by a state-licensed pharmacy. Ask Henry Meds for the all-in price at the maintenance dose, what is charged today and how often, and which pharmacy fills the prescription. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does Henry Meds charge for tirzepatide?
As of November 20, 2026, no current compounded tirzepatide price is shown for Henry Meds: its page read on its own page on November 20, 2026 (changed since the last read). This record shows no figure rather than an outdated one presented as current.
Is Henry Meds’s tirzepatide FDA-approved?
No. Compounded tirzepatide from any telehealth program, Henry Meds included, is not FDA-approved and is not the same product as Zepbound or Mounjaro. It is made for an individual patient by a state-licensed compounding pharmacy. Brand Zepbound is the FDA-approved version.
Where do these Henry Meds figures come from?
From Henry Meds’s own page (first-party read, changed, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Henry Meds pricing page (read November 20, 2026)